SPOTLIGHT: Sunesis cuts 60 jobs

Sunesis Pharmaceuticals is realigning to focus on the development voreloxin (SNS-595), its lead drug candidate. The company is expanding activities around late-stage development of the drug and reduced its workforce by 60 percent. The plan includes de-emphasizing research work. Sunesis said the move concentrates the company's assets "on the strongest path to potential near-term value creation for the company's stockholders." Release